Cell No. : Cell Name
RCB0808 : MMAc
update : 2024/09/11
|
| Comment | Human melanoma, spindle-shaped. Said DOPA (+). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Katayama, Hiroshi
|
| Originator |
Katayama, Hiroshi
|
| Year of deposit |
1992
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Female
|
| Age at sampling |
39 years
|
| Tissue |
melanoma, ascites meta
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
liver, lymph node et
|
| Classification |
cancer
|
| Year of origin |
1992
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_5951
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP, MPI, PepB
|
| Chromosome mode |
|
46-232(50) : /76(7),77(7),78(3),79(1),80(6),81(5)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
13
|
| User's Publication |
|
19970
Kawahara R, Usami T, Arakawa S, Kamo H, Suzuki T, Komatsu R, Hara H, Niwa Y, Shimizu E, Dohmae N, Shimizu S, Simizu S.
Biogenesis of fibrils requires C-mannosylation of PMEL
FEBS J
2023
290(22):5373-5394
PubMed ID: 37552474
DOI: 10.1111/febs.16927
|
|
20799
Fujimoto M, Takii R, Matsumoto M, Okada M, Nakayama KI, Nakato R, Fujiki K, Shirahige K, Nakai A.
HSF1 phosphorylation establishes an active chromatin state via the TRRAP-TIP60 complex and promotes tumorigenesis.
Nat Commun
2022
13(1):4355
PubMed ID: 35906200
DOI: 10.1038/s41467-022-32034-4
|
|
12521
Hayashi Y, Jia W, Kidoya H, Muramatsu F, Tsukada Y, Takakura N.
Galectin-3 Inhibits Cancer Metastasis by Negatively Regulating Integrin β3 Expression
Am J Pathol
2019
189(4):900-910
PubMed ID: 30653955
DOI: 10.1016/j.ajpath.2018.12.005
|
|
7328
Kim HJ, Kim JS, Woo JT, Lee IS, Cha BY.
Hyperpigmentation mechanism of methyl 3,5-di-caffeoylquinate through activation of p38 and MITF induction of tyrosinase.
Acta Biochim. Biophys. Sin. (Shanghai)
2015
47:548-56
PubMed ID: 26018825
DOI: 10.1093/abbs/gmv040
|
|
7375
Kim HJ, Kim IS, Dong Y, Lee IS, Kim JS, Kim JS, Woo JT, Cha BY.
Melanogenesis-inducing effect of cirsimaritin through increases in microphthalmia-associated transcription factor and tyrosinase expression.
Int J Mol Sci
2015
16:8772-88
PubMed ID: 25903150
DOI: 10.3390/ijms16048772
|
|
18797
Saito A, Saito N, Mol W, Furukawa H, Tsutsumida A, Oyama A, Sekido M, Sasaki S, Yamamoto Y.
Simvastatin inhibits growth via apoptosis and the inducti
Melanoma Res
2008
18(2):85-94
PubMed ID: 18337644
DOI: 10.1097/CMR.0b013e3282f60097
|
|
3689
Nobeyama Y, Okochi-Takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, Nakanishi Y, Nakagawa H, Ushijima T.
Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas.
Int J Cancer
2007
121(2):301-7
PubMed ID: 17372906
DOI: 10.1002/ijc.22637
|
|
3445
Furuta, Junichi, Nobeyama, Yoshimasa, Umebayashi, Yoshihiro, Otsuka, Fujio, Kikuchi, Kanako, Ushijima, Toshikazu
Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
Cancer Res
2006
66:6080-6
PubMed ID: 16778180
DOI: 10.1158/0008-5472.CAN-06-0157
|
|
3093
Furuta, Junichi, Kaneda, Atsushi, Umebayashi, Yoshihiro, Otsuka, Fujio, Sugimura, Takashi, Ushijima, Toshikazu
Silencing of the thrombomodulin gene in human malignant melanoma.
Melanoma Res
2005
15:15-20
PubMed ID: 15714116
DOI: 10.1097/00008390-200502000-00004
|
|
13482
Tsutsumida A, Hamada J, Tada M, Aoyama T, Furuuchi K, Kawai Y, Yamamoto Y, Sugihara T, Moriuchi T.
Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines
Int J Oncol
2004
25(5):1415-21
PubMed ID: 15492833
|
|
15609
Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T.
Promoter methylation profiling of 30 genes in human malignant melanoma
Cancer Sci
2004
95(12):962-8
PubMed ID: 15596045
DOI: 10.1111/j.1349-7006.2004.tb03184.x
|
|
3688
Satomi H1, Wang B, Fujisawa H, Otsuka F.
Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner.
Cytokine
2002
18(2):108-15
PubMed ID: 12096926
DOI: 10.1006/cyto.2002.1028
|
|
13483
Okubo Y, Hamada J, Takahashi Y, Tada M, Tsutsumida A, Furuuchi K, Aoyama T, Sugihara T, Moriuchi T.
Transduction of HOXD3-antisense into human melanoma cells results in decreased invasive and motile activities
Clin Exp Metastasis
2002
19(6):503-11
PubMed ID: 12405287
DOI: 10.1023/a:1020346211686
|
Back
Top
CELL BANK Website